Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
arcticnovartis
- Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer
- Kisqali® NATALEE oral presentation to report prognostic and predictive impact of gene expression from largest biomarker CDK4/6i trial dataset
- Scemblix® ASC4FIRST oral presentation to feature longer-term 144-week efficacy, safety and tolerability data in first-line Ph+ CML-CP